drugset
drugset / Trial / NCT05630274

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

NCT05630274 ↗

Phase 1 Completed 32 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
RandomizedCrossoverDouble-blindBasic science

Summary

The main purpose of this study is to assess the effect of Selpercatinib (LY3527723) on the heart rate-corrected QT (QTc) interval. The study will last up to 41 days.

Timeline

Start
2019-04-16
Primary completion
2019-06-21
Completion
2019-06-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject Selpercatinib Small molecule 320 mg Oral
Subject Selpercatinib Small molecule 640 mg Oral

Indications

No indication recorded.